132 related articles for article (PubMed ID: 21367927)
1. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1.
Gatti D; Viapiana O; Idolazzi L; Fracassi E; Rossini M; Adami S
J Clin Endocrinol Metab; 2011 May; 96(5):1555-9. PubMed ID: 21367927
[TBL] [Abstract][Full Text] [Related]
2. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin and DKK1 in primary hyperparathyroidism.
Viapiana O; Fracassi E; Troplini S; Idolazzi L; Rossini M; Adami S; Gatti D
Calcif Tissue Int; 2013 Apr; 92(4):324-9. PubMed ID: 23430197
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin.
Gatti D; Viapiana O; Adami S; Idolazzi L; Fracassi E; Rossini M
Bone; 2012 Mar; 50(3):739-42. PubMed ID: 22178539
[TBL] [Abstract][Full Text] [Related]
6. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
[TBL] [Abstract][Full Text] [Related]
7. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
8. Teriparatide treatment in adult patients with osteogenesis imperfecta type I.
Gatti D; Rossini M; Viapiana O; Povino MR; Liuzza S; Fracassi E; Idolazzi L; Adami S
Calcif Tissue Int; 2013 Nov; 93(5):448-52. PubMed ID: 23907723
[TBL] [Abstract][Full Text] [Related]
9. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.
Dobnig H; Sipos A; Jiang Y; Fahrleitner-Pammer A; Ste-Marie LG; Gallagher JC; Pavo I; Wang J; Eriksen EF
J Clin Endocrinol Metab; 2005 Jul; 90(7):3970-7. PubMed ID: 15840739
[TBL] [Abstract][Full Text] [Related]
10. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.
Xu XJ; Shen L; Yang YP; Lu FR; Zhu R; Shuai B; Li CG; Wu MX
Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821
[TBL] [Abstract][Full Text] [Related]
11. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
12. Serum Dickkopf 1 levels in sclerostin deficiency.
van Lierop AH; Moester MJ; Hamdy NA; Papapoulos SE
J Clin Endocrinol Metab; 2014 Feb; 99(2):E252-6. PubMed ID: 24302746
[TBL] [Abstract][Full Text] [Related]
13. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
[TBL] [Abstract][Full Text] [Related]
14. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.
Glover SJ; Eastell R; McCloskey EV; Rogers A; Garnero P; Lowery J; Belleli R; Wright TM; John MR
Bone; 2009 Dec; 45(6):1053-8. PubMed ID: 19679211
[TBL] [Abstract][Full Text] [Related]
15. Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study.
Liakou CG; Mastorakos G; Makris K; Fatouros IG; Avloniti A; Marketos H; Antoniou JD; Galanos A; Dontas I; Rizos D; Tournis S
Endocrine; 2016 Nov; 54(2):543-551. PubMed ID: 27601021
[TBL] [Abstract][Full Text] [Related]
16. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study.
Ardawi MS; Rouzi AA; Al-Sibiani SA; Al-Senani NS; Qari MH; Mousa SA
J Bone Miner Res; 2012 Dec; 27(12):2592-602. PubMed ID: 22836717
[TBL] [Abstract][Full Text] [Related]
17. Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation.
Sridharan M; Cheung J; Moore AE; Frost ML; Fraser WD; Fogelman I; Hampson G
Calcif Tissue Int; 2010 Nov; 87(5):398-405. PubMed ID: 20838781
[TBL] [Abstract][Full Text] [Related]
18. Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients.
Wang N; Xue P; Wu X; Ma J; Wang Y; Li Y
Endocr Res; 2018 Feb; 43(1):29-38. PubMed ID: 28972408
[TBL] [Abstract][Full Text] [Related]
19. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
20. Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone.
Idolazzi L; Fassio A; Tripi G; Braga V; Viapiana O; Adami G; Rossini M; Gatti D
Clin Rheumatol; 2017 Apr; 36(4):925-928. PubMed ID: 28054306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
